NASDAQ · GLPG
Healthcare · Biotechnology
$27.73
Up+$0.47 (+1.71%)
Updated Sep 14, 2026, 12:38 AM
SID Score
3.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
GLPG does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning GLPG.
GLPG research
Company profile and research snapshot.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 23, 2026 | DEGROOF PETERCAM | Hold | — |
No generated briefing is available yet.
Benzinga · Mar 31, 2026
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional
Benzinga · Mar 6, 2026
Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that its Board of Directors created 1,750,000 subscription rights under a new subscription right plan.On March 6, 2026, the
SeekingAlpha · Feb 26, 2026
Benzinga · Feb 25, 2026
RBC Capital analyst Brian Abrahams maintains Galapagos (NASDAQ:GLPG) with a Sector Perform and raises the price target from $32 to $33.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning GLPG.
